Introduction
Excessive birthweight is associated with adverse maternal and fetal outcomes (1, 2) . For the mother, the risk of cesarean and instrumental vaginal delivery, perineal lacerations, and postpartum hemorrhage is increased (2) (3) (4) . Macrosomic and large-for-gestational-age (LGA) infants are more likely to experience traumatic vaginal delivery, birth asphyxia, and mortality (2, 3, 5, 6) . In addition, excessive birthweight has been associated with long-term morbidities, such as childhood obesity, type 2 diabetes mellitus, and asthma (7, 8) . In cases of suspected excessive birthweight, timing of delivery by elective cesarean section or induction of labor might reduce these risks, but previous studies have shown poor performance of current methods in predicting macrosomia and LGA (9) (10) (11) . Therefore, more risk factors for excessive birthweight must be identified.
In recent years, investigation of risk factors for smallfor-gestational-age infants has received great interest, and a number of risk factors have been identified (12, 13) . In contrast, little attention has been paid to the risks for excessive birthweight in low-risk populations. The majority of previous studies on excessive birthweight have investigated the influence of maternal diabetes and maternal weight on birthweight (11) . Research on fetal growth has relied on the presumptions that biological variations in fetal growth are minimal in early pregnancy and that abnormal growth appears in late pregnancy. Hence, the majority of studies on prediction of excessive birthweight by ultrasound have focused on evaluation in late pregnancy (14, 15) . Recently, research also focused to find predictors of excessive birthweight in early pregnancy but the relation between ultrasound-estimated fetal growth in early pregnancy and risk of excessive birthweight in normal-weight, healthy mothers has not been specifically studied (16, 17) . In our study, we sought to investigate the impact of accelerated fetal growth, as estimated by ultrasound in early pregnancy, on the risk for severe excessive birthweight in a low-risk population.
Material and methods

Data source
Data on maternal, delivery, and infant characteristics were obtained from the population-based Stockholm-Gotland obstetric database. The database obtains information from all antenatal, ultrasound, delivery, and postnatal care units in the counties of Stockholm and Gotland in Sweden. From the first antenatal visit, midwives record information about maternal reproductive history, smoking habits, height, weight, and state of health. Biometric measurements used in the study were collected from all ultrasound units in the region, and information about infant birthweight, maternal diabetes, hypertension, and preeclampsia was obtained from standard delivery charts and diagnoses at discharge from the delivery hospital.
Study population
The study population included singleton deliveries (72 309) with available data on biometric measurements in the first and early second trimester in Stockholm and Gotland between 1 January 2008 and 22 October 2014. From this population, we excluded pregnancies with malformations [International Statistical Classification of diseases -10th edition (ICD-10) codes Q00-Q99] and stillbirths (3.8%), patients with prepregnancy diabetes or hypertension (1.1%), and deliveries without data on infant birthweight (0.01%), resulting in a final study population of 68 771 deliveries (see Supplementary material, Figure S1 ). Prepregnancy diabetes mellitus was defined by discharge diagnoses according to the ICD-10 codes O240, O241, and hypertension before pregnancy was defined as treatment with antihypertensive medication at first antenatal visit or ICD-10 diagnosis indicating chronic hypertension (O10, O11).
Exposures
The exposure was growth discrepancy at early second-trimester ultrasound expressed in days. First trimester (12-14 gestational weeks) ultrasound is recommended to pregnant mothers aged 35 years or older to evaluate the risk for chromosomal disorders (combined ultrasound and biochemistry examination). The examination is also available to mothers younger than 35 years on request. All women are offered an early second-trimester (18-20 gestational weeks) ultrasound to calculate the expected date of delivery and to detect multiple pregnancies or fetal malformations. These ultrasound examinations are free of charge, and in 2014, 57% of all mothers in the Stockholm-Gotland region underwent first-trimester scans, while 98% underwent early second-trimester scans (18) .
We defined the discrepancy in growth as the difference in days between fetal age estimated by early second-trimester scan and expected gestational age based on the first-trimester scan. Expected gestational age at second-trimester scan was calculated by adding the number of days between the two examinations to the estimated gestational age obtained from the first-trimester scan. At both first-and second-trimester ultrasound examinations, gestational age was estimated using fetal biparietal diameter (BPD) and according to the formula by Selbing and Kjessler (gestational age = 58.65 + (1.07 9 BPD) + (0.0138 9 BPD 2 ) (19). The ultrasound examinations were performed by specially trained midwives, using a standardized protocol. The Swedish Association for Obstetrics and Gynecology recommends that the fetal BPD should be measured from the outer edge of the proximal parietal bone to the inner edge of the distal parietal bone at the level of thalami and septum pellucidum. At the early second-trimester scan, the fetal size is expressed in days of gestational age and estimated fetal weight is not calculated. To enable clinical application of our results and in accordance with literature, discrepancies were categorized as follows: <À2 days, À2 to 2 days (reference), >2 to <7 days, and ≥7 days. A positive discrepancy in days represented fetuses that were larger than expected at the early second-trimester ultrasound examination.
Outcome
The outcome measure was excessive infant birthweight defined as a severely LGA infant (birthweight greater than the 97th centile according to the sex-specific Swedish reference curve for fetal growth) or macrosomia [birthweight of ≥4500 g at term (≥37 weeks)] (20) . The core outcome set was not used because no relevant core outcome set has been developed (21) .
Covariates
The selection of covariates recorded at the first antenatal visit [maternal age at delivery, parity, early pregnancy body mass index (BMI), maternal height, smoking in early pregnancy, and in vitro fertilization] was based on a directed acyclic graph and logistic regression analysis (see Supplementary material, Figure S2 and Table S1 ). Gestational age at birth was based on biometrical measurements obtained at first ultrasound and calculated according to the formula by Selbing and Kjessler (19) . Hypertension during pregnancy was defined as a blood pressure ≥140/90 during pregnancy on two separate occasions at least 6 h apart. Preeclampsia was defined as new onset of hypertension and proteinuria (+2 or more or +1 measured twice in subsequent samples at least 6 h apart) after 20 gestational weeks or corresponding ICD-10 diagnosis (O14, O15). Gestational diabetes was defined as ICD-10 diagnosis O24. ICD codes were provided by the responsible doctor at discharge from the hospital after delivery, and information regarding blood pressure measurements, proteinuria, and medication was provided by midwives at antenatal care or at the hospital before delivery. Mothers' countries of birth were divided into Sweden, other Nordic countries (Norway, Denmark, Finland, and Iceland), and non-Nordic countries. Information on paternal characteristics was not available in the database.
Statistical analyses
Descriptive statistics were used to calculate rates of infant birthweight by maternal, delivery, and infant characteristics as presented in Table 1 . Infants' birthweights were categorized into five groups based on centiles according to birthweight for gestational age and sex: >97th centile, 97th to >90th centile, 90th to 10th centile, <10th to 3rd centile, and <3rd centile. The p-value was calculated as a linear function.
Risk for severe LGA (>97th centile) and macrosomia was calculated based on discrepancy in fetal growth in days at early second-trimester scan, using À2 to 2 days as the reference group. The risk was estimated by multivariable unconditional logistic regression analysis and expressed as crude and adjusted odds ratios (aORs) with 95% CIs. Adjustments were made for maternal age, height, BMI, smoking, parity, in vitro fertilization, and country of birth.
In the analysis of risk for macrosomia (birthweight ≥4500 g), only term pregnancies were included (gestational age ≥37 weeks). We also calculated the risk of severe LGA and macrosomia in only mothers with normal early pregnancy BMI (18.5-24.9 kg/m 2 ). The statistical software package SAS 9.4 version 6.1 (SAS Institute, Cary, NC, USA) was used for analysis.
Ethical approval
The regional ethical committee in Stockholm, Sweden approved the study protocol on 21 January 2015 (2015/ 1:1). No written informed consent for participation in the study was obtained from participants because data were depersonalized before the analysis. Mothers included in the study were not involved in the development of the research.
Results
In total, 68 771 pregnancies were eligible for the study. Based on the biometric measurements, 14 028 (20.4%) of the fetuses had a positive discrepancy of >2 days between the first and early second-trimester ultrasounds. In 32 398 (47.1%) of the fetuses, discrepancy between estimated and expected gestational age did not differ by >2 days. Severe LGA and macrosomia were more common among older, multiparous mothers who were overweight or obese and those born in the Nordic countries (Table 1) . Mothers aged ≥35 years had increased risk of having LGA and macrosomic infant (see Supplementary material, Table S1 ) and risk of LGA and macrosomia remained elevated but of lower magnitude in the adjusted analyses (aOR 1.25; 95% CI 1.04-1.50 and aOR 1.24; 95% CI 1.05-1.46, respectively).
LGA and macrosomia were less common among smoking mothers (1.6 and 1.0%, respectively) compared with non-smoking mothers (2.7%). Gestational diabetes was diagnosed in 428 pregnancies (0.6%). Mothers with gestational diabetes delivered LGA and macrosomic infants more often (23.6 and 9.1%, respectively) than mothers without gestational diabetes (2.5 and 3.1%, respectively) (data not shown in tables). Compared with fetuses with a discrepancy of no more than 2 days at early second-trimester ultrasound, fetuses with ≥7-day discrepancy had 80% increased risk for severe LGA (Table 2 ). In contrast, fetuses with a positive discrepancy <7 days did not experience an elevated risk of LGA. Restricted analysis was performed in 68 343 pregnancies without history of gestational diabetes.
Similar associations were seen between a discrepancy of ≥7 days at early second-trimester scan and risk of macrosomia at term (≥37 weeks) ( Table 3) . Risks were, if anything, similar for macrosomia at term for fetuses with accelerated growth in early pregnancy (≥7 days) than observed for LGA (Tables 2 and 3 ). The risk of LGA and macrosomia was also elevated among mothers without gestational diabetes (Tables 2 and 3) . Next, the analysis of LGA and macrosomia risk was performed in 46 807 women with normal BMI (18.5-24.9 kg/m 2 ). Compared with the fetuses in the reference group (fetal growth discrepancy À2 to +2 days in the early second trimester), fetuses with discrepancy of ≥7 days had an increased risk of being born LGA and macrosomic (aOR 2.29; 95% CI 1.43-3.68 and aOR 2.27; 95% CI 1.49-3.45, respectively).
Discussion
In this large population-based cohort study, we found that accelerated fetal growth during early pregnancy increases the risk of excessive birthweight. In mothers without gestational diabetes and with a normal BMI, the risk of having LGA or macrosomic infant was elevated when the fetuses were ≥7 days larger than expected at the second-trimester scan.
The main strengths of this study are the large size of the cohort, prospectively recorded information, and ultrasound-based fetal growth estimation. The large cohort size made it possible to predict rare pregnancy outcomes, such as severe LGA (>97 centile) and macrosomia at term (≥4500 g). Ultrasound examinations are free of charge in the region, commonly performed, and assumed to be the most accurate method for fetal growth estimation (22) . Still, the generalizability of our conclusions might be limited, because the population characteristics are predominantly similar to other large city populations, which might differ from the wider birthing population.
No universally agreed criteria exist for defining macrosomia and LGA (23) . Previous studies have suggested that the definition of LGA should be restricted to infants with birthweights >97th centile (two standard deviations above the mean), as this more accurately describes infants who are at greatest risk for perinatal morbidity (3, 24) . We defined severe excessive birthweight as birthweight >97th centile for gestational age and sex, and macrosomia as birthweight ≥4500 g at term because the risk for maternal and neonatal morbidities is greatest in this subgroup of infants with excessive birthweight (3, 5, 25) . Restricted to pregnancies without gestational diabetes. Table 3 . Risk for macrosomia a (birthweight ≥4500 g) at term, in relation to the discrepancy between estimated and expected fetal size at early second-trimester scan in term pregnancies (≥37 weeks). Fetal birthweight is determined by a complex interplay between genetic and environmental factors. Fetal predispositions dependent on mother, such as maternal stature, BMI, and country of birth, were included in the analyses, as were environmental exposures, such as cigarette smoking. Maternal BMI and gestational diabetes are wellknown risk factors for excessive birthweight (26) . Mothers with prepregnancy diabetes and hypertension were excluded to minimize confounding caused by the influence of insulin and insulin-like growth factors or the impact of pathological placentation on early fetal growth due to abnormal spiral artery implantation (27, 28) . Consistent with previous observations, overweight status, obesity, and gestational diabetes were more common among mothers giving birth to LGA and macrosomic infants. However, in the analysis restricted to healthy mothers with normal BMI and without gestational diabetes, a discrepancy of at least 7 days was still associated with a 70 and 110% increased risk of severely LGA birth and macrosomia, respectively. Our findings suggest that accelerated fetal growth may start early in pregnancy and be present among normal-weight mothers and when clinical signs of gestational diabetes are absent (29) .
The aim of our study is in accordance with pregnancy care focusing on identification of risk in pregnancy at an early gestational age (30) . Previous research in this area has focused mainly on the evaluation of macrosomia risk in diabetic and overweight mothers, whereas we wanted to investigate the risk of LGA and macrosomia in a low-risk population (31, 32) . Recently, Nicolaides and colleagues reported the influence of maternal characteristics and fetal biometry on prediction of LGA (>95th centile) (17) . Although they investigated several risk factors associated with LGA, they could not predict LGA in early pregnancy and concluded that LGA screening should be at 35-37 weeks of gestation. However, the authors emphasize the importance of identifying pregnancies at risk in early pregnancy and thereby allowing for appropriate surveillance and intervention during pregnancy and delivery. Previous research has addressed the relation between early accelerated fetal growth and increased LGA risk, but that study was based on the discrepancy in estimated gestational ages between calculations based on date of last menstrual period and those based on ultrasound scan. Similar to the study investigating accelerated early fetal growth, expressed in discrepancy between last menstrual period and crownto-rump length, we concluded that excessive birthweight manifests in the first trimester (33) . To avoid the imprecision of last menstrual period data, we used measurements obtained at two subsequent scans. As we investigated the growth of the same biophysical characteristic (BPD) using the same dating formula at both scans, we were able to minimize the uncertainty introduced when two different methods to assess fetal growth are used. Fetal growth in early pregnancy can be expressed in growth percentiles or days (22, 34) . As we focus on the implementation of our results in clinical settings, we chose to express the accelerated fetal growth as a positive discrepancy between firsttrimester and early second-trimester scans, in days. In clinical practice today, fetal growth in early pregnancy is expressed as gestational age in days, which makes this method easy to implement in existing practice.
Previous studies have hypothesized that, in infants who display accelerated weight gain, potential epigenetic changes in utero could be the reason for development of adipose tissue in the first trimester of pregnancy (35, 36) . Exposure to excessive nutrition and adverse environments could result in epigenetic modifications affecting adipocyte development (37) . Our findings support the hypothesis that accelerated fetal growth starts as early as in the first trimester of pregnancy, even in low-risk populations. Today, there are no current recommendations on management of pregnancies with accelerated early fetal growth. Early identification of accelerated growth could allow for interventions, such as counseling on nutrition and exercise, and thereby reduce severely LGA, macrosomic births and associated negative outcomes for mother and infant. Further research is needed to investigate the early excessive fetal growth and neonatal outcome.
Conclusion
In summary, our study provides results that can form the basis for identifying mothers whose infants have increased risk of excessive fetal growth. We conclude that accelerated fetal growth in early pregnancy is a risk factor for severe LGA and macrosomia at term among women without prepregnancy diabetes and/or hypertension. Therefore, accelerated fetal growth in early pregnancy can be used to identify mothers who might benefit from prenatal interventions that could then lead to a reduction in adverse events associated with LGA and macrosomia for both mother and infant (1, 38) .
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